Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2026-06-01

Kx-826 Phase III Clinical Trial And Combination Therapy Study Data For Aga Presented At The 2026 World Congress For Hair Research (Wchr 2026), And Was Selected As An Outstanding Poster

Suzhou, 1 June, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed and potential first-in-class KX-826 data from two important clinical studies was presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28 to 31, 2026.
Picture Name

2026-03-18

Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint

Suzhou, 18 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase III Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results.
Picture Name

2026-03-17

Strategic Cooperation Framework Agreement With Chicmax In Relation To KT-939

Suzhou, 17 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that  Suzhou Kintor Pharmaceuticals, Inc. ( “ Suzhou Kintor ”), a wholly-owned subsidiary of the Company,  entered into the exclusive strategic cooperation framework agreement (the “ Framework Agreement ”) in the cosmetics sector with Shanghai Chicmax Cosmetic Co., Ltd. (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), “ Chicmax ”) in relation to the rapid commercialization of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor